Florian Hiemeyer
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.
Journal: Cancer research communications
Published: September 03, 2024
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Journal: Clinical pharmacology and therapeutics
Published: September 12, 2023
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 27, 2023
Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
Journal: JCO precision oncology
Published: February 26, 2021
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: January 08, 2021
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Journal: Blood advances
Published: July 10, 2020
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Journal: American journal of hematology
Published: December 06, 2019
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Journal: Leukemia
Published: November 21, 2019
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 05, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 22, 2017
Last Updated: 09/26/2026